Holen Sie sich die Stockscreener-App
22.86
3.44%
0.76
Handel nachbörslich:
22.86
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4.6%What's Next? - MarketBeat
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
Pacira BioSciences, Inc. Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry - marketscreener.com
PCRX Earnings History & Surprises | EPS & Revenue Results | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - Sahm
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Pacira BioSciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-02-27 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownWhat's Next? - MarketBeat
Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating - marketscreener.com
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Zacks Investment Research
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative - Sahm
Pacira BioSciences Q4 Earnings Call Highlights - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Releases Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
Pacira BioSciences reports fourth quarter and full-year 2025 financial results - marketscreener.com
Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint - MSN
Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Pacira (PCRX) Q4 2025 Earnings Call Transcript - AOL.com
Pacira Biosciences (PCRX) Projects Robust Growth in FY26 with St - GuruFocus
Pacira Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Pacira BioSciences Inc. (PCRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Pacira BioSciences Q4 Earnings Assessment - Benzinga
BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million - TradingView
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Healthcare Innovator with 28.58% Potential Upside - DirectorsTalk Interviews
Pacira Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Pacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Can Pacira BioSciences Inc expand its profit margins2025 Valuation Update & Detailed Earnings Play Alerts - baoquankhu1.vn
Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court - TipRanks
Can Pacira BioSciences Inc. stock deliver sustainable ROEQuarterly Profit Review & AI Driven Stock Reports - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
MSN Money - MSN
Pacira BioSciences (PCRX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Closer Look at Its 36.49% Potential Upside - DirectorsTalk Interviews
Is Pacira BioSciences Inc. trading at a discountEarnings Risk Report & Consistent Profit Trade Alerts - mfd.ru
Understanding Momentum Shifts in (PCRX) - Stock Traders Daily
Will Pacira BioSciences Inc. (82P) stock gain from lower interest ratesWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Should you avoid Pacira BioSciences Inc. stock right nowLong Setup & AI Enhanced Trading Signals - mfd.ru
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit - GuruFocus
Should you avoid Pacira BioSciences Inc stock right nowJuly 2025 Setups & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Pacira BioSciences (PCRX) CEO receives 261,818 stock units award - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira to Report 2025 Financial Results on Thursday February 26, 2026 - GlobeNewswire
Is Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Price Struggling As A Result Of Its Mixed Financials? - simplywall.st
Does Pacira BioSciences Inc. have declining or rising EPSEarnings Beat & Real-Time Buy Signal Alerts - mfd.ru
Pacira BioSciences Highlights Positive Impact of NOPAIN Act on Non-Opioid Pain Management in New Survey Findings - Quiver Quantitative
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices - GlobeNewswire
Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc - MarketBeat
U.S. hospitals report fewer opioids after surgery under NOPAIN Act - Stock Titan
AmacaThera Named Life Sciences Ontario Emerging Company of the Year - Bolsamania
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira (PCRX) Issues Inducement Awards to New Employees Under 20 - GuruFocus
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away (NASDAQ:PCRX) - Seeking Alpha
Pacira hands new hires $21.02 stock options and RSUs - Stock Titan
0.21%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):